ArticleNeuro-oncology advances
A Cre-mediated copy number variant compromises the reliability of a
Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The developmental context in which genetic alterations occur is crucial to understand disease progression. In pediatric cancer, modeling tumor formation in the right cell type is necessary to faithfully recapitulate the unique nature of pediatric tumors. The Cre-LoxP system is a powerful tool to modulate gene expression in specific cell types at discrete developmental time windows. Methods: We used Cre-LoxP mouse models to study the role of the oncofetal transcription factor Results: We generated a new model for Conclusions: Our work demonstrates the necessity of copy-number analysis when working with transgenic Cre-LoxP mouse models. Assessing CNVs should become a standard evaluation procedure when reporting new tumor models, preventing misleading conclusions that could dramatically impact the reliability of preclinical studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.